drugset / Trial / NCT01545583
A Study of LY3016859 in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the safety and tolerability of LY3016859 administered as single doses, and to determine how long LY3016859 remains in the body
Timeline
- Start
- 2012-04
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fepixnebart | Monoclonal antibody | 0.1 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 1 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 250 mg | Intravenous |
| Subject | Fepixnebart | Monoclonal antibody | 750 mg | Intravenous |
Indications
No indication recorded.